Acute Monocytic Leukemia

10

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Acute Monocytic Leukemia is an early-stage landscape with 10 programs across 8 companies. The most active players are AbbVie, Teva, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

AbbVie

1 program

Teva

1 program

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Chipscreen Biosciences, Ltd.

1 program

EMD Serono

2 programs

Pfizer

1 program

Pipeline

Programs by Phase

Preclinical

No programs

Phase 1

No programs

Phase 24

Venetoclax

AbbVie

Cytarabine

Teva

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Chidamide

Chipscreen Biosciences, Ltd.

Phase 35

Idarubicin

Pfizer

Cladribine

EMD Serono

Mitoxantrone

EMD Serono

G-CSF

Arog Pharmaceuticals, Inc.

Sorafenib

Bayer

Approved1

Cyclophosphamide

Baxter Healthcare Corporation

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05566054·92 enrolled

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)